Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,61 USD | 0,00% | -2,42% | -10,14% |
Omzet 2022 | 42,01 mln. 39,2 mln. | Omzet 2023 | 39,55 mln. 36,9 mln. | Marktkapitalisatie | 26,7 mln. 24,92 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -5 mln. -4,67 mln. | Nettowinst (verlies) 2023 | -6 mln. -5,6 mln. | EV/omzet 2022 | 0,8 x |
Nettoschuld 2022 | 1,2 mln. 1,12 mln. | Nettoschuld 2023 | 107K 99,7K | EV/omzet 2023 | 0,68 x |
K/w-verhouding 2022 |
-5,88
x | K/w-verhouding 2023 |
-4,07
x | Werknemers | 91 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 55,94% |
Recentste transcriptie over Cumberland Pharmaceuticals Inc.
1 week | -2,42% | ||
Lopende maand | -4,17% | ||
1 maand | -5,85% | ||
3 maanden | -15,26% | ||
6 maanden | -20,69% | ||
Lopend jaar | -10,14% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
A. Kazimi
CEO | Chief Executive Officer | 65 | 07-01-99 |
John Hamm
DFI | Director of Finance/CFO | 67 | 01-01-19 |
James Herman
CMP | Compliance Officer | 67 | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Brown
BRD | Director/Board Member | 59 | 15-07-22 |
A. Kazimi
CEO | Chief Executive Officer | 65 | 07-01-99 |
Ken Krogulski
BRD | Director/Board Member | 66 | 18-01-17 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
25-04-24 | 1,61 | 0,00% | 167 |
24-04-24 | 1,61 | -1,83% | 4 498 |
23-04-24 | 1,64 | +1,23% | 6 778 |
22-04-24 | 1,62 | +1,25% | 2 182 |
19-04-24 | 1,6 | -3,03% | 786 |
uitgestelde koers Nasdaq, 25 april 2024 om 17:04 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-10,14% | 22,82 mln. | |
+18,59% | 22,25 mld. | |
+13,49% | 14,39 mld. | |
+12,83% | 13,55 mld. | |
+38,02% | 11,27 mld. | |
-9,80% | 6,95 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+6,29% | 5,01 mld. | |
-5,36% | 4,51 mld. |